KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)

AbCellera Biologics (ABCL) has disclosed Receivables - Other for 2 consecutive years, with $62.1 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $62.1 million, compared with a TTM value of $62.1 million through Jun 2021, changed N/A, and an annual FY2020 reading of $212.3 million, changed N/A over the prior year.
  • Receivables - Other was $62.1 million for Q2 2021 at AbCellera Biologics, down from $193.1 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $212.3 million in Q4 2020 and bottomed at $62.1 million in Q2 2021.